A REVIEW ON EBOLA VIRUS DISEASE

Ketki K. Ghute; Khalid Shaikh; Nandkishor B. Bavage; Vidyasagar Gali; Shyamlila B. Bavage

A REVIEW ON EBOLA VIRUS DISEASE

Authors: Ketki K. Ghute, Khalid Shaikh, Nandkishor B. Bavage, Vidyasagar Gali, Shyamlila B. Bavage

Unique Paper ID: 149399
Volume: 6
Issue: 12
PageNo: 200-204

Keywords: Classification Structure Transmission Symptom Diagnosis Prevention Treatment

Abstract:
MkZaire ebolavirus, more commonly known as Ebola virus (EBOV),and Ebola hemorrhagic disease (EHD)is one of six known species within the genusEbolavirus. This is fatal viral hemorrhagic illness, is due to infection with the Ebola virus of the Filoviridae family. The first outbreak occurred in the Democratic Republic of Congo (formerly Zaire) in a village near the Ebola River, which gave the virus its name. Ebola was firstly described in 1976 and since then occurred sporadically in Central Africa. The 2014 Ebola outbreak in West Africa is the largest in history. As of May 20, 2015 the cumulative number, suspected,diagnosis and laboratory-confirmed cases attributed to Ebola virus was 26, 969, including 11,135 deaths. the difficulty in stopping its spread, and the lack of an effective treatment captured the worldâ€™s attention. The Ebola virus is transmitted among humans through close and direct physical contact with infected bodily fluids, the most infectious being blood, faeces and vomit.Clinical presentation:symptoms of Ebola virus fever,headach,joint and muscle aches,weakness,diarrhea,vomiting,stomach pain,lack of appetite ,Rash,red eye,hiccupscough,redeye, skin rash.treatment:- balancing the patientâ€™s fluids and electrolytes,maintaining their oxygen status and blood pressure and treating a patient for any complicating infection.

Download article

email to a friend

Cite This Article

ISSN: 2349-6002
Volume: 6
Issue: 12
PageNo: 200-204

A REVIEW ON EBOLA VIRUS DISEASE

Available:https://ijirt.org/Article?manuscript=149399

11 Jan, 2022

EVALUATION OF MARKETED EFFERVESCENT TABLETS

13 Oct, 2021

Bacterial Biofilm Inhibitor

02 Aug, 2021

The risk of death caused by the use of norepinephrine-resistant hypotension in the condition of septic shock in a patient

02 Aug, 2021

COMPUTER AIDED DRUG DESIGN (CADD)

29 Jul, 2021

Impact : Of Second Wave Covid-19 In world

29 Jul, 2021

The use of milrinone for curing a chronic heart failure

26 Jul, 2021

Leprosy Disease review

20 Jul, 2021

Transdermal Drug Delivery System

13 Jul, 2021

IBUPROFEN: AN OVERVIEW

13 Jul, 2021

CHEMOTHERAPY FOR BREAST CANCER

Impact Factor
8.01 (Year 2024)

UGC Approved
Journal no 47859

Join Our IPN

IJIRT Partner Network

Submit your research paper and those of your network (friends, colleagues, or peers) through your IPN account, and receive 800 INR for each paper that gets published.

Join Now

Latest Publication

Recent Conferences

NCSEM 2024

National Conference on Sustainable Engineering and Management - 2024 Last Date: 15th March 2024

Submit inquiry